Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate.
Simpson
E
E
O'Brien
S G
SG
Reilly
J T
JT
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D001752:Blast Crisis / Q000188:drug therapy*; D001932:Brain Neoplasms / Q000556:secondary; D017809:Fatal Outcome; D005260:Female; D006411:Hematopoiesis, Extramedullary / Q000187:drug effects; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D012074:Remission Induction; D012878:Skin Neoplasms / Q000556:secondary
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate